An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (MORPHEUS C-Gastric and Gastroesophageal Junction Carcinoma)
Sponsor: Hoffmann-La Roche
Terminated
Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
A observational or N/A phase clinical study on Gastric and Gastroesophageal Junction Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Hoffmann-La Roche and has accumulated 23 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
23 versions recorded-
Apr 16, 2026 — Present [daily]
Terminated
Status: Completed → Terminated · Phase: PHASE1/PHASE2 → None
-
Nov 2025 — Apr 2026 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 18 earlier versions
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Feb 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Oct 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced gastric carcinoma (GC) or gastroesophageal junction carcinoma (GEJC). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and modify the participant population. Cohort 1 will enroll participants with inoperable locally advanced, metastatic, or advanced GC or GEJC, with adenocarcinoma confirmed as the predominant histology, who have not received prior systemic therapy for advanced or metastatic disease. Eligible participants will initially be randomly assigned to one of treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Ganzhou, China , Hangzhou, China , Hangzhou, China , Hefei, China , Jining, China , Nanjing, China , Nantong, China , Taiyuan, China and 1 more location